Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]IS3010
- Development stage
- Preclinical
- Lead developer
- iSeek Biopharma
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[177Lu]IS3010 is a preclinical, LFA-1-targeted radioligand therapeutic being developed by iSeek Biopharma as part of its ORION immuno-oncology theranostic program. It consists of a small-molecule ligand targeting lymphocyte function-associated antigen-1 (LFA-1; integrin alpha-L/beta-2) labeled with the beta-emitting radionuclide lutetium-177 (177Lu). LFA-1 is constitutively expressed on leukocytes and is overexpressed in certain hematologic cancers and immune cells within the tumor microenvironment. By targeting LFA-1, [177Lu]IS3010 delivers localized, cytotoxic radiation directly to LFA-1-expressing cells, offering a potential therapeutic approach for immuno-oncology indications. It is designed as a theranostic pair alongside the diagnostic PET imaging agent [64Cu]IS3000.
- Other names
- 177Lu-IS3010ORION therapeutic arm[177Lu]-IS3010
02
Targets
LFA-1 (Integrin αLβ2)
Beyond the preview
Go deeper on [177Lu]IS3010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]IS3010.